Skip to main content

Table 1 Patient and disease characteristics at baseline

From: Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer

 

Arm A (n = 40)

Arm B (n = 41)

 

n

(%)

n

(%)

Received treatment

39

(97.5)

38

(92.7)

Age, years

    

   Median (range)

63 (35–77)

63 (48–74)

Gender

    

   Male

33

(82.5)

32

(78.0)

   Female

7

(17.5)

9

(22.0)

ECOG performance status

    

   0

19

(47.5)

20

(48.8)

   1

16

(40)

16

(39)

   2

4

(10)

3

(7.3)

   Missing

1

(2.5)

2

(4.9)

Histological classification

    

   Adenocarcinoma

22

(55)

23

(56.1)

   Epidermoidal carcinoma

14

(35)

12

(29.3)

   Other NSCLC

4

(10)

6

(14.6)

Site of disease

    

   Lung ± lymph nodes

14

(35)

14

(34.1)

   Lung and 1 metastatic site

12

(30)

15

(36.6)

   Lung and ≥ 2 metastatic sites

9

(22.5)

10

(24.4)

   Extra-pulmonary disease

5

(12.5)

2

(4.9)

Previous surgery for neoplastic disease

    

   Yes

4

(10)

5

(13)

Palliative

4

 

2

 

Curative

0

 

3

 

   No

35

(90)

33

(87)